Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight

The metastatic castration-resistant prostate cancer market is poised for substantial growth over the coming years, driven by the rising prevalence of advanced prostate cancer and continuous innovation in treatment options. Additionally, the ongoing late-stage clinical development of...